Patient with short bowel syndrome and atypical progression of endometrial adenocarcinoma
Keywords:
short bowel syndrome, endometrial adenocarcinoma, soft-tissue metastasisAbstract
The most common location of distant metastasis of endometrial adenocarcinoma is the lung, although sometimes it could appear soft tissue involvement. Short bowel syndrome can potentially cause serious electrolite changes that require a global management. Patient admitted for severe electrolyte changes secondary to a short bowel syndrome after an intestinal resection. Octreotide LAR was successfully used to control intestinal losses. During the outpatient follow up was detected two soft tissue masses in gluteal region compatible with tumour progression of an endometrial adenocarcinoma diagnosed 10 years before. The usefulness of octreotide to control chronic diarrhoea in short bowel syndrome and other diseases should be taken into account as an option for the management of these diseases. The presence of soft tissue masses in a patient with a history of endometrial adenocarcinoma should alert on the possibility of tumour progression at that level.
Downloads
Metrics
References
Kurra V, Krajewski KM, Jagannathan J, Giardino A, Berlin S, Ramaiya N. Typical and atypical metastatic sites of recurrent endometrial carcinoma. Cancer Imaging. 2013 Mar 26; 13: 113-22.
Kumpf VJ. Pharmacologic management of diarrhea in patients with short bowel syndrome. J Parenter Enteral Nutr. 2014 May; 38(1 Suppl): 38S-44S.
Nehra V, Camilleri M, Burton D, Oenning L, Kelly DG. An open trial of octreotide long-acting release in the management of short bowel syndrome. Am J Gastroenterol. 2001 May; 96(5): 1494-8.
Gómez-Herrera E, Farías-Llamas OA, Gutiérrez-de la Rosa JL, Hermosillo-Sandoval JM. The role of long-acting release (LAR) depot octreotide as adjuvant management of short bowel disease. Cir Cir. 2004 Sep-Oct; 72(5): 379-86.
Gregersen T, Grønbæk H, Worsøe J, Schlageter V, Laurberg S, Krogh K. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors. Scand J Gastroenterol. 2011 Jul; 46(7-8): 895-902.
Van den Heuvel B, Peeters M, Hendlisz A, Van den Eynde M, Machiels G, Dero I, et al. Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept. Minerva Chir. 2016 Jan 15. [Epub ahead of print].
Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol. 2007 Jan; 62(1): 28-34; discussion 35-6.
Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol. 1984 Jan; 17(1): 85-103.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 I Novo-Veleiro, C Macía-Rodríguez, V Alende-Castro, E Páez-Guillán, A García-Villafranca
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
